Vitiligo is an acquired autoimmune skin disorder which leads to cutaneous depigmentations. A
lot of progress has been made to unravel the pathophysiology of vitiligo. Several independent
studies confirmed the elevated values of IL-17 in the serum of vitiligo patients and higher
IL-17 values have been linked to a higher affected body surface area and a longer disease
duration. The study will be a pilot trial with secukinumab in patients with active,
non-segmental vitiligo. All patients will receive the active compound (= no placebo arm) as
the purpose of the study is to investigate the potential efficacy of secukinumab in vitiligo.